Protagonist Therapeutics, Inc 4

Insider William D. Waddill exercised 9,000 stock options and sold 9,000 shares of Protagonist Therapeutics, Inc. common stock for about $1.06 million under a 10b5-1 plan.

On June 23, 2026, William D. Waddill, a reporting insider of Protagonist Therapeutics, Inc., exercised 9,000 stock options with a strike price of $16.54 and immediately sold 9,000 shares of common stock at a weighted average price of $117.94 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. The option exercise, for which no exercise price is shown in the derivative table (but is referenced in the common stock line as $16.54), resulted in newly issued shares that were then sold for gross proceeds of approximately $1.06 million, while the options involved were already fully vested. Following these transactions, Waddill’s direct beneficial ownership in Protagonist common stock decreased to 7,825 shares, representing an estimated remaining equity position of about $0.92 million based on the reported sale price context. The activity reflects routine monetization of equity compensation through a planned exercise-and-sell transaction rather than an open-market discretionary purchase or sale.

Filing Facts

CIK

1377121

Ticker

PTGX

Form

4

Source Type

fda

Accession

0001104659-26-077761

Alert Tier

7